Insider Selling: Insmed (NASDAQ:INSM) CEO Sells $1,979,794.84 in Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 13,396 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $147.79, for a total transaction of $1,979,794.84. Following the completion of the sale, the chief executive officer directly owned 301,185 shares of the company’s stock, valued at $44,512,131.15. The trade was a 4.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

William Lewis also recently made the following trade(s):

• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The stock was sold at an average price of $156.34, for a total transaction of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $158.93, for a total value of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The shares were sold at an average price of $169.00, for a total value of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total value of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total value of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $166.97, for a total value of $1,786,412.03.

Insmed Stock Performance

INSM stock opened at $148.75 on Friday. Insmed, Inc. has a one year low of $60.40 and a one year high of $212.75. The firm has a market cap of $31.72 billion, a price-to-earnings ratio of -24.03 and a beta of 1.11. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. The firm has a 50-day simple moving average of $169.05 and a two-hundred day simple moving average of $161.50.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently modified their holdings of INSM. IFP Advisors Inc increased its holdings in Insmed by 29.5% in the 2nd quarter. IFP Advisors Inc now owns 2,423 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 552 shares during the period. LRI Investments LLC acquired a new stake in shares of Insmed in the second quarter worth $59,000. Yousif Capital Management LLC acquired a new stake in shares of Insmed in the second quarter worth $201,000. Sagespring Wealth Partners LLC purchased a new position in shares of Insmed during the second quarter worth $254,000. Finally, Allianz Asset Management GmbH lifted its position in Insmed by 6.8% during the second quarter. Allianz Asset Management GmbH now owns 80,422 shares of the biopharmaceutical company’s stock valued at $8,094,000 after purchasing an additional 5,138 shares during the period.

Analyst Ratings Changes

INSM has been the subject of a number of recent analyst reports. TD Cowen set a $241.00 price objective on Insmed in a research report on Thursday, December 18th. Wells Fargo & Company set a $195.00 price target on Insmed in a research note on Thursday, December 18th. The Goldman Sachs Group boosted their price target on Insmed from $225.00 to $258.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. UBS Group decreased their price objective on shares of Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research report on Tuesday, January 6th. Finally, Cantor Fitzgerald boosted their target price on shares of Insmed from $216.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Insmed has a consensus rating of “Buy” and an average price target of $204.24.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.